Rubius Therapeutics, Inc. – NASDAQ:RUBY
Rubius Therapeutics stock price today
$0.09
+0.03
+57.72%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Rubius Therapeutics stock price monthly change
+200.00%
month
Rubius Therapeutics stock price quarterly change
+251.85%
quarter
Rubius Therapeutics stock price yearly change
-61.43%
year
Rubius Therapeutics key metrics
Market Cap | N/A |
Enterprise value | N/A |
P/E | -0.01 |
EV/Sales | N/A |
EV/EBITDA | 0.07 |
Price/Sales | N/A |
Price/Book | 0.11 |
PEG ratio | N/A |
EPS | -2.59 |
Revenue | N/A |
EBITDA | -118.35M |
Income | -233.74M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRubius Therapeutics stock price history
Rubius Therapeutics stock forecast
Rubius Therapeutics financial statements
| Mar 2022 | 0 | -53.96M | |
|---|---|---|---|
| Jun 2022 | 0 | -45.57M | |
| Sep 2022 | 0 | -92.92M | |
| Dec 2022 | 0 | -41.28M |
| Mar 2022 | 267123000 | 132.47M | 49.59% |
|---|---|---|---|
| Jun 2022 | 229082000 | 133.54M | 58.29% |
| Sep 2022 | 170697000 | 134.11M | 78.57% |
| Dec 2022 | 23070000 | 7.93M | 34.41% |
| Mar 2022 | -47.13M | -80.84M | 76K |
|---|---|---|---|
| Jun 2022 | -34.28M | -1.76M | 156K |
| Sep 2022 | -36.20M | 77.87M | 0 |
| Dec 2022 | -32.51M | 17.67M | -75.70M |
Rubius Therapeutics alternative data
| Aug 2023 | 6 |
|---|---|
| Sep 2023 | 6 |
| Oct 2023 | 6 |
| Nov 2023 | 6 |
| Dec 2023 | 6 |
| Jan 2024 | 6 |
| Feb 2024 | 6 |
| Mar 2024 | 6 |
| Apr 2024 | 6 |
| May 2024 | 6 |
| Jun 2024 | 6 |
| Jul 2024 | 6 |
Rubius Therapeutics other data
75.35%
-11.54%
of RUBY is owned by hedge funds
50
-16
68.01M
-10.32M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2022 | 30000 | 0 |
| Aug 2022 | 0 | 5737 |
| Jan 2023 | 0 | 9833 |
| Feb 2023 | 0 | 22711 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | APPELHANS DANNIELLE officer: CEO and President | Common Stock | 10,385 | $0.13 | $1,319 | ||
Sale | APPELHANS DANNIELLE officer: CEO and President | Common Stock | 3,878 | $0.25 | $970 | ||
Sale | CAGNONI PABLO J director | Common Stock | 8,448 | $0.25 | $2,112 | ||
Option | TURKA LAURENCE A. officer: Chief Sc.. | Restricted Stock Units | 8,625 | N/A | N/A | ||
Sale | TURKA LAURENCE A. officer: Chief Sc.. | Common Stock | 2,593 | $0.24 | $622 | ||
Option | TURKA LAURENCE A. officer: Chief Sc.. | Common Stock | 8,625 | N/A | N/A | ||
Option | CAGNONI PABLO J director | Restricted Stock Units | 25,000 | N/A | N/A | ||
Sale | CAGNONI PABLO J director | Common Stock | 7,240 | $0.24 | $1,745 | ||
Option | CAGNONI PABLO J director | Common Stock | 25,000 | N/A | N/A | ||
Option | APPELHANS DANNIELLE officer: CEO and President | Restricted Stock Units | 7,500 | N/A | N/A |
| Patent |
|---|
Application Filling date: 27 Sep 2021 Issue date: 24 Mar 2022 |
Application Filling date: 18 Nov 2021 Issue date: 10 Mar 2022 |
Application Filling date: 17 Nov 2021 Issue date: 10 Mar 2022 |
Application Filling date: 27 May 2021 Issue date: 23 Sep 2021 |
Application Filling date: 1 Jun 2020 Issue date: 12 Aug 2021 |
Application Filling date: 16 Oct 2020 Issue date: 17 Jun 2021 |
Grant Utility: Functionalized erythroid cells Filling date: 16 Feb 2018 Issue date: 1 Jun 2021 |
Application Filling date: 4 Nov 2020 Issue date: 20 May 2021 |
Application Filling date: 4 Nov 2020 Issue date: 6 May 2021 |
Grant Filling date: 13 Mar 2015 Issue date: 22 Dec 2020 |
| Quarter | Transcript |
|---|---|
| Q4 2019 12 Mar 2020 | Q4 2019 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Pablo J. Cagnoni Ph.D., M.D. (1963) Chief Executive Officer, Pres & Director | $1,010,000 |
| Mr. Laurence A. Turka M.D. (1958) Chief Scientific Officer and Head of Research & Translational Medicine | $704,940 |
Mr. David R. Epstein B.Sc., M.B.A. (1962) Executive Chairman | $495,000 |
-
What's the price of Rubius Therapeutics stock today?
One share of Rubius Therapeutics stock can currently be purchased for approximately $0.09.
-
When is Rubius Therapeutics's next earnings date?
Unfortunately, Rubius Therapeutics's (RUBY) next earnings date is currently unknown.
-
Does Rubius Therapeutics pay dividends?
No, Rubius Therapeutics does not pay dividends.
-
What is Rubius Therapeutics's stock symbol?
Rubius Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "RUBY".
-
What is Rubius Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Rubius Therapeutics?
Shares of Rubius Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Rubius Therapeutics's key executives?
Rubius Therapeutics's management team includes the following people:
- Dr. Pablo J. Cagnoni Ph.D., M.D. Chief Executive Officer, Pres & Director(age: 62, pay: $1,010,000)
- Mr. Laurence A. Turka M.D. Chief Scientific Officer and Head of Research & Translational Medicine(age: 67, pay: $704,940)
- Mr. David R. Epstein B.Sc., M.B.A. Executive Chairman(age: 63, pay: $495,000)
-
How many employees does Rubius Therapeutics have?
As Jul 2024, Rubius Therapeutics employs 6 workers.
-
When Rubius Therapeutics went public?
Rubius Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 18 Jul 2018.
-
What is Rubius Therapeutics's official website?
The official website for Rubius Therapeutics is rubiustx.com.
-
Where are Rubius Therapeutics's headquarters?
Rubius Therapeutics is headquartered at 399 Binney Street, Cambridge, MA.
-
How can i contact Rubius Therapeutics?
Rubius Therapeutics's mailing address is 399 Binney Street, Cambridge, MA and company can be reached via phone at +61 76799600.
Rubius Therapeutics company profile:
Rubius Therapeutics, Inc.
rubiustx.comExchange:
NASDAQ
Full time employees:
6
Industry:
Biotechnology
Sector:
Healthcare
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
399 Binney Street
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001709401
ISIN: US78116T1034
CUSIP: 78116T103
